Risk stratification in the era of novel therapies

Cancer Journal

Volumn 15, Issue 6, 2009, Pages 457-464

  San Miguel, Jesus ^a,b   Mateos, M Victoria ^a   Gutierrez, Norma C ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

Author keywords

Bortezomib; Deletion 17p; Early relapse; High S phase; High Risk myeloma; Lenalidomide; T(14; 16); T(4; 14); Thalidomide

Indexed keywords

BORTEZOMIB; CARMUSTINE; CYCLIN D; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; MICRORNA; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ANTIGEN EXPRESSION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CANCER TRANSPLANTATION; CELL PROLIFERATION; CHROMOSOME 13Q; CHROMOSOME 17P; CYTOGENETICS; DIPLOIDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HUMAN; KARYOTYPE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PATHOGENESIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; RISK ASSESSMENT; STRATIFICATION; TREATMENT RESPONSE; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DOXORUBICIN; GENE EXPRESSION PROFILING; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; PROTEASE INHIBITORS; PROTEIN KINASE INHIBITORS; PYRAZINES; RISK ASSESSMENT; THALIDOMIDE;

EID: 75149115877     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181c51efa     Document Type: Review

References (66)

1. Hideshima T, Bergsagel PL, Kuehl WM, et al. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607-618.
2. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007;21:529-534.
3. San-Miguel J, Harousseau JL, Joshua D, et al. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol. 2008;26: 2761-2766.
4. San-Miguel JF, Mateos MV, Pandiella A. Novel drugs for multiple myeloma. Hematol J. 2006;2:205-211.
5. Richardson PG, Sonneveld P, Schuster MW, et al; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498.
6. Dimopoulos M, Spencer A, Attal M, et al; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123-2132.
7. Weber D, Knight R, Chen C, et al. Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma (ASH Annual Meeting Abstracts). Blood. 2007;110:128a.
8. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-917.
9. San Miguel JF, Garcia-Sanz R. Prognostic features of multiple myeloma. Best Pract Res Clin Haematol. 2005;18:569-583.
10. Fonseca R, San MJ. Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am. 2007;21:1115-1140.
11. Greipp PR, San MJ, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
12. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569-4575.
13. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109:3489-3495.
14. Gutierrez NC, Castellanos MV, Martin ML, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia. 2007;21:143-150.
15. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546-1558.
16. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108:1724-1732.
17. Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copynumber alterations in multiple myeloma. J Clin Oncol. 2009;27:4585-4590.
18. Gonzalez-Paz N, Chng WJ, McClure RF, et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood. 2007;109:1228-1232.
19. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020-2028.
20. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276-2284.
21. Decaux O, Lode L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol. 2008;26:4798-4805.
22. Armellini A, Sarasquete ME, Garcia-Sanz R, et al. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. Br J Haematol. 2008;141:212-215.
23. Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 2008;105:12885-12890.
24. Roccaro AM, Sacco A, Thompson B, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009;113:6669-6680.
25. Gutierrez NC, Sarasquete ME, Delgado M. MicroRNA expression profiling in multiple myeloma: correlation with genetic abnormalities. Blood. 2008;112: 629a.
26. Bergsagel PL, Kuehl WM, Zhan F, et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296-303.
27. Debes-Marun CS, Dewald GW, Bryant S. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia. 2003;17:427-436.
28. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032-1037.
29. Morgan RJ Jr, Gonchoroff NJ, Katzmann JA, et al. Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma. Am J Hematol. 1989;30:195-200.
30. Shimazaki C, Gotoh H, Ashihara E, et al. Immunophenotype and DNA content of myeloma cells in primary plasma cell leukemia. Am J Hematol. 1992;39:159-162.
31. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol. 1995;90:106-112.
32. San Miguel JF, Garcia-Sanz R, Gonzalez M, et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood. 1995;85:448-455.
33. Greipp PR, Trendle MC, Leong T, et al. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk Lymphoma. 1999;35: 83-89.
34. Gutierrez NC, Garcia JL, Hernandez JM, et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood. 2004;104:2661-2666.
35. Greipp PR, Lust JA, O'Fallon WM, et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382-3387.
36. San Miguel JF, Garcia-Sanz R, Gonzalez M, et al. Immunophenotype and DNA cell content in multiple myeloma. Baillieres Clin Haematol. 1995;8: 735-759.
37. Garcia-Sanz R, Gonzalez-Fraile MI, Mateo G, et al. Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer. 2004;112:884-889.
38. San Miguel JF, Gonzalez M, Gascon A, et al. Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol. 1991;77:185-190.
39. Pellat-Deceunynck C, Barille S, Puthier D, et al. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res. 1995;55:3647-3653.
40. Robillard N, Jego G, Pellat-Deceunynck C, et al. CD28, a marker associated with tumoral expansion in multiple myeloma. Clin Cancer Res. 1998;4:1521-1526.
41. Mateo G, Montalban MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008;26:2737-2744.
42. Van de Velde H, Liu X, Chen G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92:1399-1406.
43. Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26:5775-5782.
44. Harousseau JL, Weber D, Dimopoulos M, et al. Relapsed/refractory multiple myeloma patients treated with lenalidomide/dexamethasone who achieve a complete or near complete response have longer overall survival and time to progression compared with patients achieving a partial response (ASH Annual Meeting Abstracts). Blood. 2007;110:1052a.
45. Harousseau JL, Palumbo A, Richardson P. Superior outcomes associated with complete response: analysis of the phase III VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood. 2008;112:2778a.
46. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473.
47. Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112:4017-4023.
48. Sarasquete ME, Garcia-Sanz R, Gonzalez D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90:1365-1372.
49. Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82:323-341.
50. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
51. Cavo M, Testoni N, Terragna C, et al. Up-front thalidomide-dexamethasone (THAL) and double autologous transplantation (Double TX) for multiple myeloma: comparison with double TX without added thalidomide and prognostic implications of chromosome 13 deletion and translocation t(4;14). Blood. 2006;108:3081a.
52. Lokhorst H, van der Holt B, Zweegman S. Final analysis of HOVON-50 randomized phase III study on the effect of thalidomide combined with adriamycine, dexamethasone (AD) and high dose melphalan (HDM) in patients with multiple myeloma (MM). Blood. 2008;112:157a.
53. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006; 108:3289-3294.
54. Morgan G, Jackson GH, Davies FE. Maintenance thalidomide may improve progression free but not overall survival; results from the myeloma IX maintenance randomisation. Blood. 2008;112:656a.
55. Barlogie B, Pineda-Roman M, van RF, et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112:3115-3121.
56. Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009;114:522-525.
57. Avet-Loiseau H, Soulier J, Fermand J. Impact of chromosomal abnormalities del(13), T(4;14), and del(17p) and prior treatment on outcomes in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2008;112:3685a.
58. Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009;114:518-521.
59. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21:151-157.
60. Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia. 2007;21:164-168.
61. Harousseau J, Mathiot C, Attal M. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial. J Clin Oncol. 2008;26:8505a.
62. Cavo M, Testoni N, Terragna C. Superior rate of complete response with up-front velcade-thalidomide-dexamethasone versus thalidomide-dexamethasone in newly diagnosed multiple myeloma is not affected by adverse prognostic factors, including high-risk cytogenetic abnormalities. Blood. 2008;112:1662a.
63. Rosinol L, Cibeira MT, Martinez J. Thalidomide/dexamethasone (TD) vs. bortezomib (velcade®)/thalidomide/dexamethasone (VTD)) vs. VBMCP/ VBAD/velcade® as induction regimens prior autologous stem cell transplantation (ASCT) in younger patients with multiple myeloma (MM): first results of a prospective phase III PETHEMA/Gem trial. Blood. 2008;112:654a.
64. Richardson P, Jagannath S, Jakubowiak A. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. Blood. 2008;112:1742a.
65. Richardson P, Lonial S, Jakubowiak A. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II Study. Blood. 2008;112:92a.
66. Barlogie B, Anaissie E, Shaughnessy J. Ninety percent sustained complete response (CR) rate projected 4 years after onset of CR in gene expression profiling (GEP)-defined low-risk multiple myeloma (MM) treated with total therapy 3 (TT3): basis for GEP-risk-adapted TT4 and TT5. Blood. 2008;112:162a.